Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1371874 10.3389/fphar.2024.1371874 Pharmacology Review Extracellular vesicles in chronic kidney disease: diagnostic and therapeutic roles Zheng et al. 10.3389/fphar.2024.1371874 Zheng Yixuan 1 Wang Hui 1 Li Xueying 2 Xie Jing 3 Fan Junming 4 5 6 * Ren Sichong 4 5 * 1 Chengdu University of Traditional Chinese Medicine, Chengdu, China 2 Department of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China 3 Chongqing Beibei Hospital of Traditional Chinese Medicine, Chongqing Hospital of the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Chengdu, China 4 Chengdu Medical College, Chengdu, China 5 Department of Nephrology, First Affiliated Hospital of Chengdu Medical College, Chengdu, China 6 Clinical Research Center for Geriatrics of Sichuan Province, Chengdu, China

Edited by: Youhua Liu, Southern Medical University, China

Reviewed by: Lin-Li Lv, Southeast University, China

Marcella Franquesa, Germans Trias i Pujol Health Science Research Institute (IGTP), Spain

 *Correspondence: Junming Fan, junmingfan@163.com; Sichong Ren, sichongren@163.com 13 03 2024 2024 15 1371874 17 01 2024 29 02 2024 Copyright © 2024 Zheng, Wang, Li, Xie, Fan and Ren. 2024 Zheng, Wang, Li, Xie, Fan and Ren

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Chronic kidney disease (CKD) is a progressive disorder characterized by structural and functional changes in the kidneys, providing a global health challenge with significant impacts on mortality rates. Extracellular vesicles (EVs), are vital in the physiological and pathological processes associated with CKD. They have been shown to modulate key pathways involved in renal injury, including inflammation, fibrosis, apoptosis, and oxidative stress. Currently, the application research of EVs in the diagnosis and treatment of CKD is highly prevalent. However, there is currently a lack of standardized guidelines for their application, and various methodologies have advantages and limitations. Consequently, we present an comprehensive summary elucidating the multifaceted involvement of EVs in both physiological and pathological aspects in CKD. Furthermore, we explore their potential as biomarkers and diverse therapeutic roles in CKD. This review provides an overview of the current state of research on application of EVs in the diagnosis and therapeutic management of CKD.

 extracellular vesicles exosomes chronic kidney disease biomarker treatment section-at-acceptance Renal Pharmacology 1 Introduction

Chronic kidney disease (CKD) is a progressive disorder that results from various causes, typically defined as a reduction in renal function, an estimated glomerular filtration rate (eGFR) of less than 60 mL/min per 1.73 m2, or markers of kidney damage (albuminuria, haematuria, or abnormalities detected through laboratory testing or imaging) are present for at least 3 months (Webster et al., 2017). CKD is caused by various factors such as diabetes, hypertension, glomerulonephritis, which lead to irreversible impairment of renal function and structure (Levey et al., 2015). Typically, CKD gradually develops into end-stage renal disease (ESRD), leading to progressive uremia, electrolyte abnormalities, anemia, mineral and bone metabolism abnormalities and acid-base imbalance. Without treatment, it will inevitably result in death (Zarantonello et al., 2021). Currently, the intervention for CKD primarily focuses on two aspects: slowing disease progression and reducing further renal damage. Notably, four scientifically validated strategies have been applied to impede the progression of kidney disease including regulating hypertension, using renin-angiotensin-aldosterone system inhibitors, managing diabetes and hyperglycemia, as well as correcting metabolic acidosis (Vassalotti et al., 2016). The global prevalence of CKD in 2017 was nearly 700 million. The global burden of CKD increased significantly by 29.3% from 1990 to 2017 (Collaboration, 2020). Although current diagnostic and treatment methods for CKD are feasible, it remains a significant threat to human health. Therefore, the exploration of more sensitive biomarkers and effective treatment approaches continues to be a major challenge in diagnosing and treating CKD.

EVs are double-layer phospholipid vesicles secreted by cells and commonly found in various body fluids or cell culture. Typically, they can be classified into three distinct groups based on their biological origins: exosomes, microvesicles (MVs), and apoptotic bodies (ABs). In recent years, EV research has received extensive attention (Elsharkasy et al., 2020). The constituents of EVs are composed of proteins (e.g., heat-shock proteins, tetraspa-nins, and Alix), lipids (e.g., ceramide and cholesterol), and nucleic acids (e.g., DNA, mRNAs, and microRNAs). With a large number of these contents, EVs shuttle between cells and tissues, transferring signals and mediating micro-environmental communication in certain diseases (Lin et al., 2019; Li et al., 2020a; Li et al., 2020b; Wang et al., 2020b). Thus, EVs can possess significant physiological and pathological functions, including immune regulation, wound healing facilitation, and modulation of tumor initiation and progression (van Balkom et al., 2011).

Currently, due to their abundant sources and stable biological activities, EVs possess remarkable diagnostic value as a minimally invasive liquid biopsy for monitoring disease progression (Colombo et al., 2014). An increasing number of EV-related diagnostic biomolecules have been identified as potential biomarkers for a wide range of diseases, including cardiovascular diseases (Hafiane and Daskalopoulou, 2018), cancer (Fitts et al., 2019), central nervous system disorders (Kanninen et al., 2016), and CKD (Zhang et al., 2016). Additionally, the therapeutic effect of EVs has emerged as prominent area of research. EVs from various sources have been shown to ameliorate the pathological status as well as postpone the progression of many diseases including CKD (Ståhl et al., 2019; Corrêa et al., 2021; Cheng and Hill, 2022). It has been reported that a wide range of cell types such as fibroblasts, epithelial cells, blood cells, adipocytes, neurons, stromal cells, tumor cells, chondrocytes and mesenchymal stem cells (MSCs), exhibited the capability to secrete EVs (Kalluri and LeBleu, 2020). Many studies have reported multiple therapeutic roles of EVs in CKD by regulating pathways involved in renal injury, including inflammation, fibrosis, apoptosis and oxidative stress. Additionally, they also facilitate renal regeneration by promoting angiogenesis and cell proliferation (Nagaishi et al., 2016; Liu et al., 2018a; Ebrahim et al., 2018). In this review, we aim to elucidate the role of EVs in the pathogenesis of CKD and primarily focus on their potential as biomarkers and therapeutic agents for CKD.

 2 Biogenesis and isolation methods of EVs 2.1 Biogenesis of EVs

The biogenesis of EVs is a highly complex process with heterogeneity defined by factors such as size, cargo composition, functional impact on recipient cells, and cellular origin. Exosomes are the most extensively studied EVs in recent years. In 1984, exosomes were first found in the supernatant of sheep erythrocytes cultured in vitro (Pan and Johnstone, 1984). Researchers noticed that certain vesicles could transfer unnecessary proteins between cells. The process of exosome generation involves two steps: first, the cell plasma membrane double invaginates, wrapping around extracellular components and cell membrane proteins to form early sorting endosomes (ESEs). Secondly, these ESEs fuse together to form intracellular multivesicular bodies (MVBs), which contain numerous intraluminal vesicles (ILVs). ILVs are then secreted as exosomes through fusion with the plasma membrane and exocytosis (Raposo and Stoorvogel, 2013).

MVs are a type of EV with diameters ranging from 100 to 1,000 nm that originate by budding from the plasma membrane. Unlike the early intracellular steps of exosome biogenesis, MV biogenesis begins with the plasma membrane budding directly outward (Clancy et al., 2021). The biogenesis mechanism begins with the outward budding and pinching of the plasma membrane (PM), which releases newly produced MVs straight into the extracellular environment (Muralidharan-Chari et al., 2009). Meanwhile, SCRT-dependent mechanisms and small GTPases may both be involved in this process (Sedgwick et al., 2015; Mathieu et al., 2019; Fang et al., 2024).

ABs are generated during the process of cell apoptosis, mainly referring to the membrane shrinkage and invagination, division and encapsulation of cytoplasm, containing DNA material and organelles, forming small EVs with a diameter ranging from 100 to 5,000 nm (Phan et al., 2020). ABs can maintain homeostasis and fine-tune the life cycle of multicellular organisms, and mediate intercellular communication (Liu et al., 2018c; Zhao et al., 2021).

 2.2 Methodology for the isolation of EVs

Various techniques can be used for the isolation and purification of EVs, such as ultracentrifugation, immunoaffinity capture, size-based isolation, and polymer precipitation (ALTINTAs and SAYLAN, 2023). Advantages, disadvantages, and methodologies of each method are discussed.

2.2.1 Ultracentrifugation

Ultracentrifugation is the most popular method for EV isolation, known as the gold standard owing to its high efficiency and low cost (Livshits et al., 2015; Ludwig et al., 2018; Poupardin et al., 2024). Because of the different densities, cells, platelets and large apoptotic bodies will be separated from EVs by this method (Witwer et al., 2013). The simplicity of the procedure and no need of sample volume limitations are both significant advantages of this method. Conversely, large sample sizes may result in a lack of purity time-consuming process and lower EV yields (Clos-Sansalvador et al., 2022). Ultracentrifugation is applicable for the isolation of EVs from various body fluids. Although plasma is one of the most challenging bodily fluid samples to handle in EV associated studies, ultracentrifugation showed the highest purity of EVs compared to several commercial isolation kits (Tian et al., 2020). However, in order to achieve higher EV purity and yield, it is essential to optimize the ultracentrifugation method. An improved one-step sucrose cushion ultracentrifugation (SUC) method was developed based on the density and buffering properties of sucrose. Compared to conventional ultracentrifugation methods, this method demonstrates higher yields of EVs with better integrity and fewer protein contaminants (Gupta et al., 2018). In future applications, the combination of ultracentrifugation with various other isolation methods is highly necessary.

 2.2.2 Size-based techniques

Size exclusion chromatography (SEC) is a common EV isolation method of size-based techniques. SEC relies on the difference in size between EVs and other components in biological samples (Benedikter et al., 2017). Compared with ultracentrifugation and precipitation-based methods, SEC causes less morphological changes in EVs, thereby maintaining their integrity and biological activity. However, the SEC relies on extensive laboratory equipment, which is time-consuming (Kumar et al., 2024). Another popular size-based EV isolation techniques is ultrafiltration. It uses membranes with diverse pore sizes to selectively capture molecules, particles, or vesicles of specific dimensions while allowing smaller components to permeate through the filter (Xu et al., 2017). Its advantages include a simple process, no need for special equipment, and a high yield (Kim et al., 2021). However, it can lead to protein residue, which poses challenges for EV downstream analysis by proteomics. Tangential flow filtration (TFF) uses a cross-flow technique to concentrate and filter particles. Compared to ultrafiltration, TFF has better membrane permeability and is capable of preventing molecular accumulation and membrane fouling. Therefore, the separation of EVs has high yield and is suitable for large-scale research applications (Veerman et al., 2021; Visan et al., 2022).

In the past decade, size-based techniques are increasingly applied for EV isolation (Poupardin et al., 2024). In clinical samples, this technique can be effectively used for the isolation of EVs from various sources including urine, plasma, serum, and tissues. Typically, the isolated EVs could be well applied to downstream analysis (Sedej et al., 2022; Mazzucco et al., 2023; Zhang et al., 2023). Therefore, EVs isolated through SEC are commonly used for protein research. However, the complex process of size-based techniques needs simplification in the future, such as simplified dichotomic SEC, which can be applied for the bulk separation of EVs in clinical research (Guo et al., 2021).

 2.2.3 Immunoaffinity-based capture

Immunoaffinity-based capture relies on the distinctive identification of surface biomarkers proteins on EVs. The method can be achieved by incubating sample with magnetic beads coated with antibodies against the surface proteins (Li et al., 2017). It is typically used as a supplementary step combined with ultracentrifugation method to further purify isolated EVs (Reiner et al., 2017). The main advantage of the method is its ability to separate specific subtype of EVs, resulting in high specificity and purity (Tschuschke et al., 2020). However, immunocapture requires a large number of antibody conjugates, leading to high costs and making it unnecessary for use with large samples. Additionally, many biological materials are added during the EV separation process, making immunoaffinity-based capture difficult to apply for treatment purposes (McNamara et al., 2018). Immunoaffinity-based capture of EVs is already possible with the development of commercial kits. Most of these kits are coated with antibodies against CD9, CD63, and CD81 (Wiklander et al., 2018). This methodology is applicable for the isolation and characterization of distinct EV subtypes, enabling high-purity research. As a result of its efficiency and sensitivity, immunoaffinity-based capture has been recognized as a useful method. However, further studies should concentrate on the development of low-cost and less biological material added method.

 2.2.4 Polymer precipitation

Polymer precipitation is achieved by reducing the solubility of EVs using polyethylene glycol (PEG) as a medium (Konoshenko et al., 2018). Due to the simple operation and high yield, polymer precipitation has ability for processing large-scale samples, and offers the advantage of reduced analysis time (Batrakova and Kim, 2015). Currently, there are mature PEG-based commercial kits, such as ExoQuick™. Polymer precipitation is commonly used for the isolation of EVs in blood and cell culture (Poupardin et al., 2024). In addition, polymer precipitation can achieve the highest yield of EVs and genetic content, such as miRNA and mRNA, compared to ultracentrifugation and ultrafiltration methods, making it suitable for subsequent analysis (Patel et al., 2019). However, one disadvantage of the method is that other unnecessary precipitates can contaminate the separated EVs, reducing their purity and recovery rate. It is not conducive to downstream proteomics and other analytical work. To address this issue, additional purification steps should be employed to remove contaminants (Zarovni et al., 2015).

 3 EVs in chronic kidney disease pathogenesis

The pathology of CKD occurs inextricably with two mechanisms: initial stimulation and persistent renal damage. Initial stimulus factors include inflammation, immune response, toxins, and underlying renal conditions. In this context, EVs participate in CKD pathogenesis through intercellular communication, facilitating content delivery and activating signaling pathways in target cells or processing pathways exclusive to cell contents (Hogan et al., 2009; Borges et al., 2013). Mechanically, EVs contribute to the pathogenesis of CKD through facilitating intercellular communication and promoting inflammation and fibrosis (Figure 1).

EVs in the pathogenesis of CKD.

 3.1 EVs in intercellular communication

Renal EVs are generated and secreted by kidney cells, and through intercellular communication, they have been linked to renal function and disorders (Krause et al., 2015). Gildea et al., 2014 demonstrated that cells in the upper segments of tubules can release EVs that can be absorbed by downstream cells, transmitting active molecules to regulate cellular behavior. Moreover, Street et al., 2011 first reported the functional transfer of AQP2 via urinary EVs in murine kidney collecting duct cells. An in vitro study showed that the activation of glomerular endothelial cells (GEnC) could induce the transfer of miR-200C-3p from GEnC to podocytes through EVs, affecting the communication between GEnC and podocytes (Hill et al., 2020). Similarly, EVs derived from injured podocytes may mediate crosstalk between glomeruli and tubules, inducing apoptosis in tubular interstitial cells and reducing tubular function (Jeon et al., 2020). Meanwhile, long-distance cell-to-cell communication mediated by EVs between distinct aspects of kidney could amplify kidney injury, tubulointerstitial fibrosis and inflammation (Munkonda et al., 2018; Hill et al., 2020). β-catenin is a master controller in renal tubular injury and fibrogenesis (Conduit et al., 2019; Miao et al., 2019). Chen et al. confirmed that β-catenin activated tubular epithelial cells to secrete EVs containing Osteopontin protein, which binded to CD44 receptors in fibroblasts, promoting their proliferation and activation (Chen et al., 2022b). Consequently, the crosstalk mediated by EVs is widespread in the kidney injury and the process of CKD. Regulating the intercellular communication of EVs in renal cells is a promising therapeutic strategy for CKD.

 3.2 EVs in inflammation

Inflammation serves as a pivotal mechanism contributing to the renal damage in CKD. EVs have the potential to trigger pro-inflammatory responses, which may be attributed to the transfer of inflammatory mediators (Mesri and Altieri, 1998; Distler et al., 2006). During inflammation, both innate immune cells and damaged cells can release EVs carrying damage associated molecular patterns (DAMPs). These DAMPs can be either attached to the surface of the EVs or encapsulated into them. Meanwhile, DAMPs can activate macrophage toll-like receptors (TLRs), leading to the stimulation of NF-κB signaling and subsequent release of inflammatory cytokines and reactive oxygen species (ROS) (Cao et al., 2015). In CKD, the injury of proximal tubular epithelial cells (TECs) is closely associated with the decline in renal function. Under hypoxia condition, stimulation of proteinuria or physical damage leads to the release of various pro-inflammatory cytokines by damaged TECs, thereby eliciting an immune response (Nangaku, 2006; Liu et al., 2018b). TECs can upregulate hypoxia-inducible factor 1α (HIF-1α) and release EVs enriched with miR-23a, which induce macrophage reprogramming under hypoxia and promoting tubulointerstitial inflammation (Li et al., 2019). Albuminuria is a significant indicator of CKD and plays a vital role in the development of tubulointerstitial inflammation related to CKD (Liu et al., 2014). It is worth noting that proteinuria-stimulated renal TECs release an increased number of EVs loaded with inflammatory cytokine CCL2 mRNA, which are directly transferred to macrophages. The transfer represents a critical initial stage in albumin-induced tubulointerstitial inflammation (Lv et al., 2018b). Although many studies have been conducted on the relationship between EVs and inflammation, several unknown mechanisms still need to be explored.

 3.3 EVs in renal fibrosis

Renal fibrosis is a crucial pathological characteristic of CKD, characterized by tubular atrophy, interstitial chronic inflammation and fibrosis, glomerulosclerosis, and vascular rarefaction. The mechanism is that renal injury leads to local fibroblast activation, continuous synthesis of extracellular matrix (ECM) proteins, resulting in ECM deposition, tissue damage, and impaired renal function (Huang et al., 2023). EVs also have a role in tubulointerstitial inflammation (Nangaku, 2006). Under hypoxia condition, damaged renal tubular epithelial cells secrete EVs containing TGF-β1 mRNA, thereby facilitating adjacent fibroblast proliferation, alpha-smooth muscle actin expression, and type I collagen production. Furthermore, extensive researches have demonstrated that the stimulation of TGF-β1 induced the release of EVs carrying miR-21 and miR-216a from TECs, thereby activating neighbor cells through the PTEN/Akt pathway to undergo epithelial-mesenchymal transition (EMT) (Zheng et al., 2018; Qu et al., 2019). In the condition of ischemia-reperfusion (IR), injured TECs were able to secrete EVs containing miR-150, which directly stimulated fibroblast and proliferation (Guan et al., 2020). The function of EVs is not only involved in initiating CKD fibrosis but also plays a key role in the progression of fibrosis is well documented. Therefore, repressing the release of EVs may thus emerge as a promising therapeutic strategy for CKD.

 4 EVs as biomarkers of chronic kidney disease

In CKD, early diagnosis holds paramount importance for optimizing clinical treatment strategies and alleviating healthcare burdens. EVs play a crucial role in the pathogenesis and progression of CKD. Simultaneously, the potential application of EVs and their cargo as biomarkers has been accepted by researchers. Moreover, compared to other biomarkers such as urinary protein or microprotein levels, EVs do not require specific collection time. The diagnostic roles of EVs in CKD will be discussed.

The expression of miR-21 is significantly upregulated in renal tissue and closely associated with renal fibrosis (Denby and Baker, 2016). This relationship has been consistently demonstrated across various animal models of kidney disease, including unilateral ureteral obstruction (UUO) and ischemia/reperfusion (I/R) models (Zarjou et al., 2011). Moreover, the urinary EV miR-21 level was significantly increased in CKD patients, and it was positively correlated with the severity of tubulointerstitial fibrosis as well as podocyte injury (Lv et al., 2018a; Lange et al., 2019). The ability of miR-29c to reduce renal fibrosis is achieved by inhibiting EMT and decreasing extracellular matrix deposition (Chung et al., 2013), which involves multiple signaling pathways such as AMPK/mTOR (Shao et al., 2019), Wnt/β-Catenin (Huang et al., 2020) and PI3K/AKT (Feng et al., 2022). Meanwhile, several studies have demonstrated that miR-29c levels in urinary EVs were significantly decreased in patients with CKD or renal fibrosis compared to healthy people (Lv et al., 2018a; Chun-Yan et al., 2018). MiR-192 specifically expresses in renal cortical tissues (Ren et al., 2021) and is closely associated with the degree of renal fibrosis, EMT, inflammation, and oxidative stress (Bhatt et al., 2016; Ma et al., 2016). Similarly, urinary EV miR-192 was significantly increased in DN patients with proteinuria, suggesting that miR-192 could be used to distinguish between normal albuminuria and microalbuminuria and provide a reference for the early diagnosis of DN (Jia et al., 2016). However, further investigation is needed to explore the correlation between miR-192 derived from EVs and other renal function indicators. Other studies showed that urinary EV miR-181a was significant reduced in CKD patients at all stages, as well as in DN patients (Khurana et al., 2017; Zha et al., 2019; Liu et al., 2022). Furthermore, miR-181a overexpression could reduce glomerulosclerosis and tubular epithelial injury (Liu et al., 2018d).

As biomarkers, miRNA panels were important substances in EVs, which exhibit potential to develop as biomarkers in CKD. For example, Eissa et al. discovered that miR-15b, miR-34a, and miR-636 were upregulated in urinary EVs of DKD patients by PCR, and these urinary EV miRNAs were validated with 100% diagnostic sensitivity in a large sample (Eissa et al., 2016). Similarly, miR-21, miR-29c and miR-150 also can predict the fibrosis progressing in Lupus Nephritis, as a urinary EV derived multimarker panel (Solé et al., 2019). Furthermore, other RNA components in EVs, such as circRNAs can be used as urine diagnostic biomarkers for CKD (Cao et al., 2022a; Cao et al., 2022b). However, this study did not determine the relationship between urinary EV derived circRNA and kidney fibrosis, a further mechanism studiy is needed.

Proteins carried by EVs also have potential as biomarkers. In diabetic nephropathy (DN), increasing urinary EV derived AFM, CP, and IGLV7-46 were upregulated with the DN progression, regucalcin protein was significantly downregulated in both urinary EVs and kidney tissue, while increasing C-megalin protein was predictive of the progression of the albuminuric stages (Zubiri et al., 2015; De et al., 2017; Du et al., 2023). The proteome of urinary EVs has already been investigated in search of potential indicators for renal diseases, however, prospective large-scale research are necessary to confirm its accuracy.

Currently, due to the stable structure of proteins, increasing numbers of studies have applied proteomics technology to search relative proteins as biomarkers in CKD. However, compared with transcriptomics technology, proteomics technology has higher cost and more complex protocol. Thus, it is essential to establish a panel of combined biomarkers for CKD using RNAs and proteins.

 5 Therapeutic role of EVs in chronic kidney disease

EV-based therapies for CKD are currently undergoing active research. EVs have shown great potential as both therapeutics and carriers for drug delivery (Table 1; Figure 2). In the field of kidney disease treatment, current research primarily focuses on the therapeutic prospects offered by EVs themselves. However, there is a lack of established systematic therapeutic regimens in this field. The therapeutic role of EVs in CKD will be discussed below, including their application as a therapeutic agent, treatment target and drug delivery carrier.

Therapeutic roles of EVs in CKD.

Kidney disease Models Source of EVs Cargos Mechanism Outcome Ref.
DN STZ-induced DN rats Ad-MSC miR-125a Regulate the activation HDAC1 and ET-1 Inhibit DN progression and alleviate the symptoms Hao et al. (2021)
RAS porcine model of metabolic syndrome and renal artery stenosis Ad-MSC - Increase reparative macrophages, upregulate the expression of IL-10 Decrease renal inflammation, attenuated renal fibrosis Eirin et al. (2017)
DN db/db mice Ad-MSC miR-486 Inhibit the Smad1/mTOR signaling pathway in podocyte Prevent renal injury from diabetes Jin et al. (2019)
RAS porcine model of metabolic syndrome and renal artery stenosis Ad-MSC - Decrease microvascular oxidative stress and apoptosis Restore renal angiogenesis and microvascular architecture Eirin et al. (2018)
CKD UUO mice BM-MSC miR-374a-5p Inhibit apoptosis by regulate MAPK6/MK5/YAP axis Prevent the progression of renal fibrosis Liang et al. (2022a)
CKD UUO mice BM-MSC miR-21a-5p Inhibit glycolysis in TECs by targeting PFKM Ameliorate renal fibrosis Xu et al. (2022)
CKD UUO rats BM-MSC miR-294, miR-133 Prevent phosphorylation of SMAD2/3 and ERK1/2 Ameliorate renal fibrosis Wang et al. (2020a)
CKD UUO mice BM-MSC miR-186-5p Downregulate the expression of Smad5 Ameliorate renal fibrosis Yang et al. (2022)
DN STZ-induced DN rats BM-MSC - Revert oxidative stress, ER stress, inflammatory condition, and apoptosis Inhibit DN progression Khamis et al. (2023)
CKD 5/6 subtotal nephrectomy mice BM-MSC - Prevent fibrosis, reduce interstitial lymphocyte infiltrates Ameliorate renal injury He et al. (2012)
CKD UUO mice BM-MSC Let-7i-5p Antagomir Regulate TSC1/mTOR signaling Reduce renal fibrosis and improve kidney function Jin et al. (2021)
CKD UUO mice Huc-MSC miR-874-3p Target RIPK1/PGAM5 to regulate programmed necrosis and mitochondrial division Attenuate renal tubular epithelial cell injury and enhance repair Yu et al. (2023)
CKD UUO mice Huc-MSC CK1δ and β-TRCP Transport CK1δ and β-TRCP system, inhibit YAP activation Reduce collagen deposition, alleviate renal fibrosis Ji et al. (2020)
DN STZ-induced DN rats Huc-MSC miR-146a-5p Facilitate M2 macrophage polarization by targeting TRAF6 Restore renal function in DN rats Zhang et al. (2022b)
DN db/db mice Huc-MSC miR-424-5p inhibit high glucose-Induce apoptosis and EMT through of YAP1 Decrease cell apoptosis, inhibit EMT Cui et al. (2022)
DN STZ-induced DN mice Huc-MSC miR-451a Inhibit cell cycle inhibitors to restart the blocked cell cycle and reverse EMT Promote the repair of injured kidney structure and function, improve EMT Zhong et al. (2018)
CKD UUO mice Primary mouse satellite cells miR-29 Downregulate YY1 and TGF-β pathway proteins Ameliorate skeletal muscle atrophy and attenuate kidney fibrosis Wang et al. (2019)

Therapeutic roles of EVs in CKD.

 5.1 EVs as a therapeutic agent in chronic kidney disease

Mesenchymal stem cells (MSCs) are a type of self-renewing pluripotent cells that can be derived from various tissues and organs. MSCs have the ability to prevent kidney injury by regulating the release of EVs. MSC-derived EVs can be delivered to the kidney through intraperitoneal, arteriovenous, and intraosseous routes, exerting their protective effects on the kidneys via paracrine mechanisms such as anti-fibrosis, anti-oxidative stress, anti-apoptosis, and pro-angiogenesis (Peired et al., 2016).

Bone marrow derived MSCs (BMMSCs) have been extensively investigated and are considered the primary source of therapeutic EVs (Pittenger et al., 1999; Tang et al., 2022). Zhang et al. (2022a) discovered that miR-16 and miR-21 in BMMSC EVs could induce the polarization of a specific anti-inflammatory macrophage phenotype within the kidneys of MRL/lpr mice, thus alleviating lupus nephritis. The miR-21a-5p carried by BMMSC EVs can effectively suppress the expression of phosphofructokinase muscle isoform, which is the rate-limiting enzyme in glycolysis, thereby reducing glycolytic activity in TECs. Consequently, this mechanism contributes to the amelioration of renal fibrosis in UUO mice (Xu et al., 2022).

The abundant source and low immunogenicity make human umbilical cord mesenchymal stem cell (hUCMSCs) a proper choice for allogeneic cell therapy, highlighting their suitability as a type of stem cells (Ding et al., 2018). HUCMSC EVs possess the benefits of hUCMSCs while evading their drawbacks (Huang et al., 2022). The protective effect of hUCMSC EVs on CKD mainly manifests through the regulation of inflammation and immunity. The presence of miR-22-3p in hUCMSC EVs exhibits anti-inflammatory and nephroprotective effects in diabetic mice by downregulating NLRP3 expression, while also conferring podocyte protection (Wang et al., 2023). MiR-146a-5p in hUCMSC EVs targeted the TRAF6/STAT1 pathway, thereby facilitating macrophage polarization towards the M2 phenotype and ameliorating renal injury in DN rats (Zhang et al., 2022b).

Compared to bone marrow and umbilical cord, adipose tissue provides a less invasive and more accessible source of stem cells (Mazini et al., 2020). Zhu et al., 2017 demonstrated that EVs derived from adipose-derived MSCs (ADMSCs) possessed the ability to counteract the AKI-CKD transition by suppressing the expression of sox9 in TECs. In the porcine model of metabolic syndrome and renal artery stenosis, Eirin et al. observed that ADMSC EVs exhibited multiple functions, including enhancing modulation of renal angiogenic factors expression, amelioration of kidney inflammation, improvement in medullary hypoxia and fibrosis, thereby presenting a potential therapeutic approach for addressing metabolic syndrome and renal artery stenosis (Eirin et al., 2017; Eirin et al., 2018).

 5.2 EVs as a therapeutic target in chronic kidney disease

As previously mentioned, EVs play a pivotal role in biological processes of CKD. Consequently, they have emerged as a promising therapeutic target for the treatment of CKD. Zhuang et al., 2022 demonstrated that GABA could mitigate the pro-inflammatory effects of macrophages on podocytes by modulating miR-21a-5p/miR-25-3p in macrophage-derived EVs. Ding et al., 2021 discovered that the exosome inhibitor GW4869 effectively attenuated cyst growth in Autosomal Dominant Polycystic Kidney Disease (ADPKD) and reduced macrophage infiltration in cystic kidneys. Moreover, systemic administration of GW4869 did not induce hepatic or renal toxicity. Pharmacological inhibition of exosome biogenesis and release, exemplified by GW4869, shows promise as a potential therapeutic strategy for the treatment of ADPKD.

Numerous traditional Chinese medicines and natural products have demonstrated efficacy in ameliorating chronic kidney disease through the utilization of EVs. Panax ginseng saponins have the potential to alleviate steroid resistance in the mouse glomerular endothelial cells (GECs) by modulating hormone-resistant signals present in lymph-derived EVs (Chen et al., 2022a). The Jian-Pi-Yi-Shen Formula exerts a reno-protective effect in adenine-induced CKD rats by attenuating the release of miR-192-5p from macrophage-derived EVs (Liang et al., 2022b).

 5.3 EVs as a drug delivery system in chronic kidney disease

EVs have been extensively considered as an efficient drug delivery system in recent years due to their compatibility, low toxicity, long half-life, non-immunogenicity, and effective targeting ability towards various cells (Rajput et al., 2022). There are two methods for packaging cargo into EVs, including endogenous and exogenous loading. Exogenous drug loading, which involves extracting and purifying EVs, and then encapsulating therapeutic drugs in EVs, has the advantage of simple preparation. Common methods include electroporation, co-incubation, ultrasound, chemical transfection, and repeated freeze-thaw cycles. Another method is endogenous drug loading, which involves using genetic engineering techniques or co incubation to introduce target molecules into donor cells, followed by secretion of extracellular vesicles from the donor cells, and finally recovering the drug loaded EVs through separation and purification (Gupta et al., 2021).

Sun et al. generated and isolated ADMSC-derived EVs overexpressing GNDF using lentiviral transduction, demonstrating significant attenuation of renal fibrosis in UUO mice. Moreover, these EVs exhibited the ability to enhance peritubular capillary angiogenesis following kidney injury by activating the SIRT1/eNOS pathway (Chen et al., 2020). Endogenous cargo involves genetically modifying parent cells to regulate the cargo during EVs biogenesis (Gupta et al., 2021). Wang et al., 2019 used engineered EVs vectors containing miRNA-29 and targeting peptide RVG, enabling specific renal targeting. In the fibrotic kidneys in UUO mice, these engineered EVs exhibited enhanced accumulation and effectively mitigated renal fibrosis by suppressing YY1 and TGF-β pathway proteins. This study demonstrates the feasibility of constructing therapeutic-loaded engineered EVs.

Besides, enhancing the targeting ability of EVs to kidney injury sites can significantly enhance the therapeutic effect of EVs in CKD. One strategy is the utilization of peptides or antibodies that exhibit specific binding affinity towards specific molecules. Kidney injury molecule-1 (Kim-1) is recognized as a marker for tubular injury in AKI (Vaidya et al., 2010). Tang et al., 2021 established a red blood cell-derived EVs (RBCEVs)based drug delivery platform and conjugated Kim-1-targeting LTH peptides to RBCEVs to target renal tubular injury. In addition, Wu et al. constructed a neutrophil membrane-engineered nanoparticle (NEX) that significantly promoted targeted enrichment of EVs in damaged renal tissue, thereby improving AKI (Wu et al., 2022). In addition, various hybrid approaches from tumor treatment models have provided valuable insights for targeted EV therapy in CKD. These methods include the hybridization of synthetic liposomes with EVs and the conjugation of diacyllipid-aptamer conjugates with EVs (Zou et al., 2019), providing support for precise targeted therapy of CKD.

 6 Conclusion and perspective

EVs in the diagnosis and treatment of CKD have made a lot of advancements, thus holding immense potential for future applications. The distinctive characteristics of EVs, including their inherent stability, biocompatibility, and capacity for intercellular biomolecule transfer, render them highly appealing candidates for non-invasive diagnostics and targeted therapeutics in CKD. However, as research progresses, the methods of EV isolation and their clinical applications still require further exploration.

Despite increasing studies about EVs have been investigated, our comprehension of the EV cellular and molecular mechanisms remains limited. The technical difficulty of precisely distinguishing specific subtypes of EVs poses a significant limitation. The development of multi-omics technology provides technical basis to reveal the mechanism of EVs. Hence, we suggest the construction of a public database using multi-omics data (genome, transcriptome, proteome, and metabolome) on EVs.

EVs are currently isolated and purified using various techniques, but there are still some areas that need improvement. Firstly, there is no standardized method for EV isolation. This lack of standardization makes it challenging to compare results across studies and hinders the reproducibility of research findings. Therefore, it is important to establish standardized isolation protocols that can be widely adopted. Secondly, most isolation methods rely on the physical characteristics of EVs, which may also co-isolate other extracellular vesicles or contaminants, leading to impure EV preparations. The combined use of EV isolation methods has become a common trend in recent years (Poupardin et al., 2024). Hence, we suggest that several strategies such as the combination of isolation methods and the use of multiple markers should be used to enhance the specificity of EV isolation.

Through extensive research and experimentation, researchers have found some potential renal-specific EV-derived biomarkers that can serve as diagnostic tools for CKD in the future. The detection of these specific markers in urine samples provides valuable insights into the underlying pathophysiology and progression of CKD, enabling early intervention and personalized treatment strategies. Nonetheless, the current studies have small sample sizes, and larger clinical samples will be necessary in the future to determine the potential of specific EVs as biomarkers. Although some EV-derived biomarkers associated with CKD have been discovered, further identification and confirmation of specific biomarkers for particular diseases are necessary. This will enhance the accuracy and reliability of EVs as biomarkers for CKD.

EVs play a pivotal role in intercellular communication and the transfer of miRNAs, mRNA, proteins, and other bioactive molecules. These properties can be exploited for therapeutic purposes in CKD. Researchers have also investigated the potential of engineering EVs to delivery therapeutic cargo, including anti-inflammatory agents, growth factors, and gene-editing tools, directly to sites of renal injury. These targeted strategies have exhibited promising outcomes in preclinical investigations, demonstrating the capacity of EVs to ameliorate renal damage, facilitate tissue regeneration, and enhance overall renal function. However, EVs in the treatment of CKD still have some issues that need to be addressed. Achieving targeted delivery and ensuring specificity remains a challenge. Novel techniques and strategies such as surface modification, specific receptor recognition, and the design of targeted delivery nanoparticles, can be developed to resolve the problem. Additionally, the safety and long-term effects of EV-based therapies need to be thoroughly assessed through rigorous preclinical and clinical studies. Furthermore, the development of EV-based drug delivery systems offers great potential for individualized and targeted CKD therapy. By engineering EVs with specific surface proteins and loading them with therapeutic agents, it becomes possible to precisely target afflicted cells or tissues, minimizing off-target effects and optimizing treatment outcomes. Moreover, the integration of EVs with nanotechnology and bioengineering approaches will facilitate the development of novel platforms for controlled release and enhanced cargo delivery to the kidneys.

Currently, the use of EVs for treating CKD is still at initial stage. Research on targeted delivery of EVs is mainly focused on the heart and tumors, with limited studies related to the kidneys. Most therapeutic studies using EVs for CKD lack material science support and overlook kidney targeting, which is an important clinical objective. Therefore, we advocate that in future research directions, emphasis should be placed on the targeting of EVs to sites of renal injury.

In conclusion, with ongoing research, technological advancements, EVs have the potential to revolutionize the field of renal diagnostics and therapeutics. The ability to non-invasively detect and monitor CKD progress, coupled with targeted and personalized treatments using EV-based platforms, holds promise for improving patient outcomes and reducing the burden of CKD worldwide.

 Author contributions

YZ: Writing–review and editing, Writing–original draft, Formal Analysis. HW: Writing–original draft, Formal Analysis. XL: Writing–original draft, Methodology. JX: Writing–original draft, Methodology. JF: Writing–review and editing, Writing–original draft, Validation, Methodology, Funding acquisition, Formal Analysis, Conceptualization. SR: Writing–original draft, Validation, Methodology, Funding acquisition, Formal Analysis, Conceptualization.

 Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work is supported by the Sichuan Province science and technology Department key research and development project (2021YFS0035), Sichuan Province natural science Foundation project (24NSFSC0253), key project of the First Affiliated Hospital of Chengdu Medical College (CYFY2021ZD01), and Chengdu Medical College from the key project (CYZZD2201).

We thank Figdraw for the figure support.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Altintas O. Saylan Y. (2023). Exploring the versatility of exosomes: a review on isolation, characterization, detection methods, and diverse applications. Anal. Chem. 95, 16029–16048. 10.1021/acs.analchem.3c02224 Batrakova E. V. Kim M. S. (2015). Using exosomes, naturally-equipped nanocarriers, for drug delivery. J. Control Release 219, 396–405. 10.1016/j.jconrel.2015.07.030 Benedikter B. J. Bouwman F. G. Vajen T. Heinzmann A. C. A. Grauls G. Mariman E. C. (2017). Ultrafiltration combined with size exclusion chromatography efficiently isolates extracellular vesicles from cell culture media for compositional and functional studies. Sci. Rep. 7, 15297. 10.1038/s41598-017-15717-7 Bhatt K. Kato M. Natarajan R. (2016). Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases. Am. J. Physiol. Ren. Physiol. 310, F109–F118. 10.1152/ajprenal.00387.2015 Borges F. T. Melo S. A. Özdemir B. C. Kato N. Revuelta I. Miller C. A. (2013). TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J. Am. Soc. Nephrol. JASN 24, 385–392. 10.1681/ASN.2012101031 Cao Q. Harris D. C. H. Wang Y. (2015). Macrophages in kidney injury, inflammation, and fibrosis. Physiol. Bethesda, Md 30, 183–194. 10.1152/physiol.00046.2014 Cao Y. Shi Y. Wang Y. Yang Y. Guo W. Zhang C. (2022a). Exosomal hsa_circ_0008925 from urine is related to chronic renal fibrosis. Dis. Markers 2022, 1899282. 10.1155/2022/1899282 Cao Y. Shi Y. Yang Y. Wu Z. Peng N. Xiao J. (2022b). Urinary exosomes derived circRNAs as biomarkers for chronic renal fibrosis. Ann. Med. 54, 1966–1976. 10.1080/07853890.2022.2098374 Cheng L. Hill A. F. (2022). Therapeutically harnessing extracellular vesicles. Nat. Rev. Drug Discov. 21, 379–399. 10.1038/s41573-022-00410-w Chen J. Zhou Q. Lu Y. (2022a). Saponins from Panax notoginseng ameliorate steroid resistance in lupus nephritis through regulating lymphocyte-derived exosomes in mice. Front. Pharmacol. 13, 946392. 10.3389/fphar.2022.946392 Chen L. Wang Y. Li S. Zuo B. Zhang X. Wang F. (2020). Exosomes derived from GDNF-modified human adipose mesenchymal stem cells ameliorate peritubular capillary loss in tubulointerstitial fibrosis by activating the SIRT1/eNOS signaling pathway. Theranostics 10, 9425–9442. 10.7150/thno.43315 Chen S. Zhang M. Li J. Huang J. Zhou S. Hou X. (2022b). β-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis. J. Extracell. Vesicles 11, e12203. 10.1002/jev2.12203 Chung A. C. Yu X. Lan H. Y. (2013). MicroRNA and nephropathy: emerging concepts. Int. J. Nephrol. Renov. Dis. 6, 169–179. 10.2147/IJNRD.S37885 Chun-Yan L. Zi-Yi Z. Tian-Lin Y. Yi-Li W. Bao L. Jiao L. (2018). Liquid biopsy biomarkers of renal interstitial fibrosis based on urinary exosome. Exp. Mol. Pathol. 105, 223–228. 10.1016/j.yexmp.2018.08.004 Clancy J. W. Schmidtmann M. D'Souza-Schorey C. (2021). The ins and outs of microvesicles. FASEB Bioadv 3, 399–406. 10.1096/fba.2020-00127 Clos-Sansalvador M. Monguió-Tortajada M. Roura S. Franquesa M. Borràs F. E. (2022). Commonly used methods for extracellular vesicles' enrichment: implications in downstream analyses and use. Eur. J. Cell Biol. 101, 151227. 10.1016/j.ejcb.2022.151227 Collaboration G. C. K. D. (2020). Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395, 709–733. 10.1016/S0140-6736(20)30045-3 Colombo M. Raposo G. Théry C. (2014). Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289. 10.1146/annurev-cellbio-101512-122326 Conduit S. E. Hakim S. Feeney S. J. Ooms L. M. Dyson J. M. Abud H. E. (2019). β-catenin ablation exacerbates polycystic kidney disease progression. Hum. Mol. Genet. 28, 230–244. 10.1093/hmg/ddy309 Corrêa R. R. Juncosa E. M. Masereeuw R. Lindoso R. S. (2021). Extracellular vesicles as a therapeutic tool for kidney disease: current advances and perspectives. Int. J. Mol. Sci. 22, 5787. 10.3390/ijms22115787 Cui C. Zang N. Song J. Guo X. He Q. Hu H. (2022). Exosomes derived from mesenchymal stem cells attenuate diabetic kidney disease by inhibiting cell apoptosis and epithelial-to-mesenchymal transition via miR-424-5p. Faseb J. 36, e22517. 10.1096/fj.202200488R Denby L. Baker A. H. (2016). Targeting non-coding RNA for the therapy of renal disease. Curr. Opin. Pharmacol. 27, 70–77. 10.1016/j.coph.2016.02.001 De S. Kuwahara S. Hosojima M. Ishikawa T. Kaseda R. Sarkar P. (2017). Exocytosis-mediated urinary full-length megalin excretion is linked with the pathogenesis of diabetic nephropathy. Diabetes 66, 1391–1404. 10.2337/db16-1031 Ding H. Li L. X. Harris P. C. Yang J. Li X. (2021). Extracellular vesicles and exosomes generated from cystic renal epithelial cells promote cyst growth in autosomal dominant polycystic kidney disease. Nat. Commun. 12, 4548. 10.1038/s41467-021-24799-x Ding M. Shen Y. Wang P. Xie Z. Xu S. Zhu Z. (2018). Exosomes isolated from human umbilical cord mesenchymal stem cells alleviate neuroinflammation and reduce amyloid-beta deposition by modulating microglial activation in alzheimer's disease. Neurochem. Res. 43, 2165–2177. 10.1007/s11064-018-2641-5 Distler J. H. W. Huber L. C. Gay S. Distler O. Pisetsky D. S. (2006). Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity 39, 683–690. 10.1080/08916930601061538 Du S. Zhai L. Ye S. Wang L. Liu M. Tan M. (2023). In-depth urinary and exosome proteome profiling analysis identifies novel biomarkers for diabetic kidney disease. Sci. China. Life Sci. 66, 2587–2603. 10.1007/s11427-022-2348-0 Ebrahim N. Ahmed I. A. Hussien N. I. Dessouky A. A. Farid A. S. Elshazly A. M. (2018). Mesenchymal stem cell-derived exosomes ameliorated diabetic nephropathy by autophagy induction through the mTOR signaling pathway. Cells 7, 226. 10.3390/cells7120226 Eirin A. Zhu X. Y. Jonnada S. Lerman A. Van Wijnen A. J. Lerman L. O. (2018). Mesenchymal stem cell-derived extracellular vesicles improve the renal microvasculature in metabolic renovascular disease in swine. Cell Transpl. 27, 1080–1095. 10.1177/0963689718780942 Eirin A. Zhu X. Y. Puranik A. S. Tang H. Mcgurren K. A. Van Wijnen A. J. (2017). Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation. Kidney Int. 92, 114–124. 10.1016/j.kint.2016.12.023 Eissa S. Matboli M. Aboushahba R. Bekhet M. M. Soliman Y. (2016). Urinary exosomal microRNA panel unravels novel biomarkers for diagnosis of type 2 diabetic kidney disease. J. Diabetes Complicat. 30, 1585–1592. 10.1016/j.jdiacomp.2016.07.012 Elsharkasy O. M. Nordin J. Z. Hagey D. W. De Jong O. G. Schiffelers R. M. Andaloussi S. E. (2020). Extracellular vesicles as drug delivery systems: why and how? Adv. Drug Deliv. Rev. 159, 332–343. 10.1016/j.addr.2020.04.004 Fang F. Yang J. Wang J. Li T. Wang E. Zhang D. (2024). The role and applications of extracellular vesicles in osteoporosis. Bone Res. 12, 4. 10.1038/s41413-023-00313-5 Feng W. Xie H. Li J. Yan X. Zhu S. Sun S. (2022). miR-29c inhibits renal interstitial fibrotic proliferative properties through PI3K-AKT pathway. Appl. Bionics Biomech. 2022, 6382323. 10.1155/2022/6382323 Fitts C. A. Ji N. Li Y. Tan C. (2019). Exploiting exosomes in cancer liquid biopsies and drug delivery. Adv. Healthc. Mater. 8, e1801268. 10.1002/adhm.201801268 Gildea J. J. Seaton J. E. Victor K. G. Reyes C. M. Bigler Wang D. Pettigrew A. C. (2014). Exosomal transfer from human renal proximal tubule cells to distal tubule and collecting duct cells. Clin. Biochem. 47, 89–94. 10.1016/j.clinbiochem.2014.06.018 Guan H. Peng R. Mao L. Fang F. Xu B. Chen M. (2020). Injured tubular epithelial cells activate fibroblasts to promote kidney fibrosis through miR-150-containing exosomes. Exp. Cell Res. 392, 112007. 10.1016/j.yexcr.2020.112007 Guo J. Wu C. Lin X. Zhou J. Zhang J. Zheng W. (2021). Establishment of a simplified dichotomic size-exclusion chromatography for isolating extracellular vesicles toward clinical applications. J. Extracell. Vesicles 10, e12145. 10.1002/jev2.12145 Gupta D. Zickler A. M. El Andaloussi S. (2021). Dosing extracellular vesicles. Adv. Drug Deliv. Rev. 178, 113961. 10.1016/j.addr.2021.113961 Gupta S. Rawat S. Arora V. Kottarath S. K. Dinda A. K. Vaishnav P. K. (2018). An improvised one-step sucrose cushion ultracentrifugation method for exosome isolation from culture supernatants of mesenchymal stem cells. Stem Cell Res. Ther. 9, 180. 10.1186/s13287-018-0923-0 Hafiane A. Daskalopoulou S. S. (2018). Extracellular vesicles characteristics and emerging roles in atherosclerotic cardiovascular disease. Metabolism Clin. Exp. 85, 213–222. 10.1016/j.metabol.2018.04.008 Hao Y. Miao J. Liu W. Cai K. Huang X. Peng L. (2021). Mesenchymal stem cell-derived exosomes carry MicroRNA-125a to protect against diabetic nephropathy by targeting histone deacetylase 1 and downregulating endothelin-1. Diabetes Metab. Syndr. Obes. 14, 1405–1418. 10.2147/DMSO.S286191 He J. Wang Y. Sun S. Yu M. Wang C. Pei X. (2012). Bone marrow stem cells-derived microvesicles protect against renal injury in the mouse remnant kidney model. Nephrol. Carlt. 17, 493–500. 10.1111/j.1440-1797.2012.01589.x Hill N. Michell D. L. Ramirez-Solano M. Sheng Q. Pusey C. Vickers K. C. (2020). Glomerular endothelial derived vesicles mediate podocyte dysfunction: a potential role for miRNA. PLoS One 15, e0224852. 10.1371/journal.pone.0224852 Hogan M. C. Manganelli L. Woollard J. R. Masyuk A. I. Masyuk T. V. Tammachote R. (2009). Characterization of PKD protein-positive exosome-like vesicles. J. Am. Soc. Nephrol. JASN 20, 278–288. 10.1681/ASN.2008060564 Huang H. Huang X. Luo S. Zhang H. Hu F. Chen R. (2020). The MicroRNA MiR-29c alleviates renal fibrosis via TPM1-mediated suppression of the wnt/β-catenin pathway. Front. Physiol. 11, 331. 10.3389/fphys.2020.00331 Huang R. Fu P. Ma L. (2023). Kidney fibrosis: from mechanisms to therapeutic medicines. Signal Transduct. Target Ther. 8, 129. 10.1038/s41392-023-01379-7 Huang Y. Chen L. Chen D. Fan P. Yu H. (2022). Exosomal microRNA-140-3p from human umbilical cord mesenchymal stem cells attenuates joint injury of rats with rheumatoid arthritis by silencing SGK1. Mol. Med. 28, 36. 10.1186/s10020-022-00451-2 Jeon J. S. Kim E. Bae Y.-U. Yang W. M. Lee H. Kim H. (2020). microRNA in extracellular vesicles released by damaged podocytes promote apoptosis of renal tubular epithelial cells. Cells 9, 1409. 10.3390/cells9061409 Jia Y. Guan M. Zheng Z. Zhang Q. Tang C. Xu W. (2016). miRNAs in urine extracellular vesicles as predictors of early-stage diabetic nephropathy. J. Diabetes Res. 2016, 7932765. 10.1155/2016/7932765 Ji C. Zhang J. Zhu Y. Shi H. Yin S. Sun F. (2020). Exosomes derived from hucMSC attenuate renal fibrosis through CK1δ/β-TRCP-mediated YAP degradation. Cell Death Dis. 11, 327. 10.1038/s41419-020-2510-4 Jin J. Qian F. Zheng D. He W. Gong J. He Q. (2021). Mesenchymal stem cells attenuate renal fibrosis via exosomes-mediated delivery of microRNA let-7i-5p antagomir. Int. J. Nanomedicine 16, 3565–3578. 10.2147/IJN.S299969 Jin J. Shi Y. Gong J. Zhao L. Li Y. He Q. (2019). Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte. Stem Cell Res. Ther. 10, 95. 10.1186/s13287-019-1177-1 Kalluri R. Lebleu V. S. (2020). The biology function and biomedical applications of exosomes. New York, N.Y.: Science, 367. Kanninen K. M. Bister N. Koistinaho J. Malm T. (2016). Exosomes as new diagnostic tools in CNS diseases. Biochimica Biophysica Acta 1862, 403–410. 10.1016/j.bbadis.2015.09.020 Khamis T. Abdelkhalek A. Abdellatif H. Dwidar N. Said A. Ahmed R. (2023). BM-MSCs alleviate diabetic nephropathy in male rats by regulating ER stress, oxidative stress, inflammation, and apoptotic pathways. Front. Pharmacol. 14, 1265230. 10.3389/fphar.2023.1265230 Khurana R. Ranches G. Schafferer S. Lukasser M. Rudnicki M. Mayer G. (2017). Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease. Rna 23, 142–152. 10.1261/rna.058834.116 Kim K. Park J. Jung J. H. Lee R. Park J. H. Yuk J. M. (2021). Cyclic tangential flow filtration system for isolation of extracellular vesicles. Apl. Bioeng. 5, 016103. 10.1063/5.0037768 Konoshenko M. Y. Lekchnov E. A. Vlassov A. V. Laktionov P. P. (2018). Isolation of extracellular vesicles: general methodologies and latest trends. Biomed. Res. Int. 2018, 8545347. 10.1155/2018/8545347 Krause M. Samoylenko A. Vainio S. J. (2015). Exosomes as renal inductive signals in health and disease, and their application as diagnostic markers and therapeutic agents. Front. Cell Dev. Biol. 3, 65. 10.3389/fcell.2015.00065 Kumar M. A. Baba S. K. Sadida H. Q. Marzooqi S. A. Jerobin J. Altemani F. H. (2024). Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct. Target Ther. 9, 27. 10.1038/s41392-024-01735-1 Lange T. Artelt N. Kindt F. Stracke S. Rettig R. Lendeckel U. (2019). MiR-21 is up-regulated in urinary exosomes of chronic kidney disease patients and after glomerular injury. J. Cell Mol. Med. 23, 4839–4843. 10.1111/jcmm.14317 Levey A. S. Becker C. Inker L. A. (2015). Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA 313, 837–846. 10.1001/jama.2015.0602 Li F.-X.-Z. Xu F. Lin X. Wu F. Zhong J.-Y. Wang Y. (2020a). The role of substance P in the regulation of bone and cartilage metabolic activity. Front. Endocrinol. 11, 77. 10.3389/fendo.2020.00077 Li Z.-L. Lv L.-L. Tang T.-T. Wang B. Feng Y. Zhou L.-T. (2019). HIF-1α inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation. Kidney Int. 95, 388–404. 10.1016/j.kint.2018.09.013 Liang M. Zhang D. Zheng D. He W. Jin J. (2022a). Exosomes from miR-374a-5p-modified mesenchymal stem cells inhibit the progression of renal fibrosis by regulating MAPK6/MK5/YAP axis. Bioengineered 13, 4517–4527. 10.1080/21655979.2022.2033465 Liang M. Zhu X. Zhang D. He W. Zhang J. Yuan S. (2022b). Yi-Shen-Hua-Shi granules inhibit diabetic nephropathy by ameliorating podocyte injury induced by macrophage-derived exosomes. Front. Pharmacol. 13, 962606. 10.3389/fphar.2022.962606 Lin X. Li F. Xu F. Cui R.-R. Xiong D. Zhong J.-Y. (2019). Aberration methylation of miR-34b was involved in regulating vascular calcification by targeting Notch1. Aging 11, 3182–3197. 10.18632/aging.101973 Li P. Kaslan M. Lee S. H. Yao J. Gao Z. (2017). Progress in exosome isolation techniques. Theranostics 7, 789–804. 10.7150/thno.18133 Liu B.-C. Tang T.-T. Lv L.-L. Lan H.-Y. (2018b). Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int. 93, 568–579. 10.1016/j.kint.2017.09.033 Liu B. Ding F.-X. Liu Y. Xiong G. Lin T. He D.-W. (2018a). Human umbilical cord-derived mesenchymal stem cells conditioned medium attenuate interstitial fibrosis and stimulate the repair of tubular epithelial cells in an irreversible model of unilateral ureteral obstruction. Nephrol. Carlt. Vic. 23, 728–736. 10.1111/nep.13099 Liu D. Chen R. Ni H. Liu H. (2022). miR-181a improved renal inflammation by targeting TNF-α in a diabetic nephropathy animal model. Nephron 146, 637–646. 10.1159/000525050 Liu D. Kou X. Chen C. Liu S. Liu Y. Yu W. (2018c). Circulating apoptotic bodies maintain mesenchymal stem cell homeostasis and ameliorate osteopenia via transferring multiple cellular factors. Cell Res. 28, 918–933. 10.1038/s41422-018-0070-2 Liu D. Xu M. Ding L.-H. Lv L.-L. Liu H. Ma K.-L. (2014). Activation of the Nlrp3 inflammasome by mitochondrial reactive oxygen species: a novel mechanism of albumin-induced tubulointerstitial inflammation. Int. J. Biochem. Cell Biol. 57, 7–19. 10.1016/j.biocel.2014.09.018 Liu L. Pang X. L. Shang W. J. Xie H. C. Wang J. X. Feng G. W. (2018d). Over-expressed microRNA-181a reduces glomerular sclerosis and renal tubular epithelial injury in rats with chronic kidney disease via down-regulation of the TLR/NF-κB pathway by binding to CRY1. Mol. Med. 24, 49. 10.1186/s10020-018-0045-2 Livshits M. A. Khomyakova E. Evtushenko E. G. Lazarev V. N. Kulemin N. A. Semina S. E. (2015). Isolation of exosomes by differential centrifugation: theoretical analysis of a commonly used protocol. Sci. Rep. 5, 17319. 10.1038/srep17319 Li X. Wang Y. Shi L. Li B. Li J. Wei Z. (2020b). Magnetic targeting enhances the cutaneous wound healing effects of human mesenchymal stem cell-derived iron oxide exosomes. J. Nanobiotechnology 18, 113. 10.1186/s12951-020-00670-x Ludwig A. K. De Miroschedji K. Doeppner T. R. Börger V. Ruesing J. Rebmann V. (2018). Precipitation with polyethylene glycol followed by washing and pelleting by ultracentrifugation enriches extracellular vesicles from tissue culture supernatants in small and large scales. J. Extracell. Vesicles 7, 1528109. 10.1080/20013078.2018.1528109 Lv C. Y. Ding W. J. Wang Y. L. Zhao Z. Y. Li J. H. Chen Y. (2018a). A PEG-based method for the isolation of urinary exosomes and its application in renal fibrosis diagnostics using cargo miR-29c and miR-21 analysis. Int. Urol. Nephrol. 50, 973–982. 10.1007/s11255-017-1779-4 Lv L.-L. Feng Y. Wen Y. Wu W.-J. Ni H.-F. Li Z.-L. (2018b). Exosomal CCL2 from tubular epithelial cells is critical for albumin-induced tubulointerstitial inflammation. J. Am. Soc. Nephrol. JASN 29, 919–935. 10.1681/ASN.2017050523 Mathieu M. Martin-Jaular L. Lavieu G. Théry C. (2019). Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17. 10.1038/s41556-018-0250-9 Ma X. Lu C. Lv C. Wu C. Wang Q. (2016). The expression of miR-192 and its significance in diabetic nephropathy patients with different urine albumin creatinine ratio. J. Diabetes Res. 2016, 6789402. 10.1155/2016/6789402 Mazini L. Rochette L. Admou B. Amal S. Malka G. (2020). Hopes and limits of adipose-derived stem cells (ADSCs) and mesenchymal stem cells (MSCs) in wound healing. Int. J. Mol. Sci. 21, 1306. 10.3390/ijms21041306 Mazzucco L. Balbo V. Zingarelli E. M. Desilvestri M. Marchioni M. Perrero L. (2023). Treatment of severe pressure ulcers with protein-enriched filtered platelet-rich plasma (PEF(PRP)): a possible management. Front. Bioeng. Biotechnol. 11, 1279149. 10.3389/fbioe.2023.1279149 Mcnamara R. P. Costantini L. M. Myers T. A. Schouest B. Maness N. J. Griffith J. D. (2018). Nef secretion into extracellular vesicles or exosomes is conserved across human and simian immunodeficiency viruses. mBio 9, e02344-17. 10.1128/mBio.02344-17 Mesri M. Altieri D. C. (1998). Endothelial cell activation by leukocyte microparticles. J. Immunol. 161, 4382–4387. Baltimore, Md, 1950. 10.4049/jimmunol.161.8.4382 Miao J. Liu J. Niu J. Zhang Y. Shen W. Luo C. (2019). Wnt/β-catenin/RAS signaling mediates age-related renal fibrosis and is associated with mitochondrial dysfunction. Aging Cell 18, e13004. 10.1111/acel.13004 Munkonda M. N. Akbari S. Landry C. Sun S. Xiao F. Turner M. (2018). Podocyte-derived microparticles promote proximal tubule fibrotic signaling via p38 MAPK and CD36. J. Extracell. Vesicles 7, 1432206. 10.1080/20013078.2018.1432206 Muralidharan-Chari V. Clancy J. Plou C. Romao M. Chavrier P. Raposo G. (2009). ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr. Biol. 19, 1875–1885. 10.1016/j.cub.2009.09.059 Nagaishi K. Mizue Y. Chikenji T. Otani M. Nakano M. Konari N. (2016). Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci. Rep. 6, 34842. 10.1038/srep34842 Nangaku M. (2006). Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. JASN 17, 17–25. 10.1681/ASN.2005070757 Pan B. T. Johnstone R. (1984). Selective externalization of the transferrin receptor by sheep reticulocytes in vitro. Response to ligands and inhibitors of endocytosis. J. Biol. Chem. 259, 9776–9782. 10.1016/s0021-9258(17)42767-0 Patel G. K. Khan M. A. Zubair H. Srivastava S. K. Khushman M. Singh S. (2019). Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci. Rep. 9, 5335. 10.1038/s41598-019-41800-2 Peired A. J. Sisti A. Romagnani P. (2016). Mesenchymal stem cell-based therapy for kidney disease: a review of clinical evidence. Stem Cells Int. 2016, 4798639. 10.1155/2016/4798639 Phan T. K. Ozkocak D. C. Poon I. K. H. (2020). Unleashing the therapeutic potential of apoptotic bodies. Biochem. Soc. Trans. 48, 2079–2088. 10.1042/BST20200225 Pittenger M. F. Mackay A. M. Beck S. C. Jaiswal R. K. Douglas R. Mosca J. D. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284, 143–147. 10.1126/science.284.5411.143 Poupardin R. Wolf M. Maeding N. Paniushkina L. Geissler S. Bergese P. (2024). Advances in extracellular vesicle research over the past decade: source and isolation method are connected with cargo and function. Adv. Healthc. Mater, e2303941. 10.1002/adhm.202303941 Qu N. Y. Zhang Z. H. Zhang X. X. Xie W. W. Niu X. Q. (2019). Microvesicles containing microRNA-216a secreted by tubular epithelial cells participate in renal interstitial fibrosis through activating PTEN/AKT pathway. Eur. Rev. Med. Pharmacol. Sci. 23, 6629–6636. 10.26355/eurrev_201908_18552 Rajput A. Varshney A. Bajaj R. Pokharkar V. (2022). Exosomes as new generation vehicles for drug delivery: biomedical applications and future perspectives. Molecules 27, 7289. 10.3390/molecules27217289 Raposo G. Stoorvogel W. (2013). Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200, 373–383. 10.1083/jcb.201211138 Reiner A. T. Witwer K. W. Van Balkom B. W. M. De Beer J. Brodie C. Corteling R. L. (2017). Concise review: developing best-practice models for the therapeutic use of extracellular vesicles. Stem Cells Transl. Med. 6, 1730–1739. 10.1002/sctm.17-0055 Ren F. J. Yao Y. Cai X. Y. Fang G. Y. (2021). Emerging role of MiR-192-5p in human diseases. Front. Pharmacol. 12, 614068. 10.3389/fphar.2021.614068 Sedej I. Štalekar M. Tušek Žnidarič M. Goričar K. Kojc N. Kogovšek P. (2022). Extracellular vesicle-bound DNA in urine is indicative of kidney allograft injury. J. Extracell. Vesicles 11, e12268. 10.1002/jev2.12268 Sedgwick A. E. Clancy J. W. Olivia Balmert M. D'Souza-Schorey C. (2015). Extracellular microvesicles and invadopodia mediate non-overlapping modes of tumor cell invasion. Sci. Rep. 5, 14748. 10.1038/srep14748 Shao H. Huang Y. Hu H. L. Fan W. X. Yin X. N. (2019). Effect of miR-29c on renal fibrosis in diabetic rats via the AMPK/mTOR signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 23, 6250–6256. 10.26355/eurrev_201907_18445 Solé C. Moliné T. Vidal M. Ordi-Ros J. Cortés-Hernández J. (2019). An exosomal urinary miRNA signature for early diagnosis of renal fibrosis in lupus nephritis. Cells 8, 773. 10.3390/cells8080773 Ståhl A.-L. Johansson K. Mossberg M. Kahn R. Karpman D. (2019). Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases. Pediatr. Nephrol. Berl. Ger. 34, 11–30. 10.1007/s00467-017-3816-z Street J. M. Birkhoff W. Menzies R. I. Webb D. J. Bailey M. A. Dear J. W. (2011). Exosomal transmission of functional aquaporin 2 in kidney cortical collecting duct cells. J. Physiol. 589, 6119–6127. 10.1113/jphysiol.2011.220277 Tang T. T. Wang B. Li Z. L. Wen Y. Feng S. T. Wu M. (2021). Kim-1 targeted extracellular vesicles: a new therapeutic platform for RNAi to treat AKI. J. Am. Soc. Nephrol. 32, 2467–2483. 10.1681/ASN.2020111561 Tang T. T. Wang B. Lv L. L. Dong Z. Liu B. C. (2022). Extracellular vesicles for renal therapeutics: state of the art and future perspective. J. Control Release 349, 32–50. 10.1016/j.jconrel.2022.06.049 Tian Y. Gong M. Hu Y. Liu H. Zhang W. Zhang M. (2020). Quality and efficiency assessment of six extracellular vesicle isolation methods by nano-flow cytometry. J. Extracell. Vesicles 9, 1697028. 10.1080/20013078.2019.1697028 Tschuschke M. Kocherova I. Bryja A. Mozdziak P. Angelova Volponi A. Janowicz K. (2020). Inclusion biogenesis, methods of isolation and clinical application of human cellular exosomes. J. Clin. Med. 9, 436. 10.3390/jcm9020436 Vaidya V. S. Ozer J. S. Dieterle F. Collings F. B. Ramirez V. Troth S. (2010). Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat. Biotechnol. 28, 478–485. 10.1038/nbt.1623 Van Balkom B. W. M. Pisitkun T. Verhaar M. C. Knepper M. A. (2011). Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. Kidney Int. 80, 1138–1145. 10.1038/ki.2011.292 Vassalotti J. A. Centor R. Turner B. J. Greer R. C. Choi M. Sequist T. D. (2016). Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am. J. Med. 129, 153–162.e7. 10.1016/j.amjmed.2015.08.025 Veerman R. E. Teeuwen L. Czarnewski P. Güclüler Akpinar G. Sandberg A. Cao X. (2021). Molecular evaluation of five different isolation methods for extracellular vesicles reveals different clinical applicability and subcellular origin. J. Extracell. Vesicles 10, e12128. 10.1002/jev2.12128 Visan K. S. Lobb R. J. Ham S. Lima L. G. Palma C. Edna C. P. Z. (2022). Comparative analysis of tangential flow filtration and ultracentrifugation, both combined with subsequent size exclusion chromatography, for the isolation of small extracellular vesicles. J. Extracell. Vesicles 11, e12266. 10.1002/jev2.12266 Wang H. Wang B. Zhang A. Hassounah F. Seow Y. Wood M. (2019). Exosome-mediated miR-29 transfer reduces muscle atrophy and kidney fibrosis in mice. Mol. Ther. 27, 571–583. 10.1016/j.ymthe.2019.01.008 Wang Y. Guo Y. F. Fu G. P. Guan C. Zhang X. Yang D. G. (2020a). Protective effect of miRNA-containing extracellular vesicles derived from mesenchymal stromal cells of old rats on renal function in chronic kidney disease. Stem Cell Res. Ther. 11, 274. 10.1186/s13287-020-01792-7 Wang Y. Liu J. Wang H. Lv S. Liu Q. Li S. (2023). Mesenchymal stem cell-derived exosomes ameliorate diabetic kidney disease through the NLRP3 signaling pathway. Stem Cells 41, 368–383. 10.1093/stmcls/sxad010 Wang Y. Xu F. Zhong J.-Y. Lin X. Shan S.-K. Guo B. (2020b). Exosomes as mediators of cell-to-cell communication in thyroid disease. Int. J. Endocrinol. 2020, 4378345. 10.1155/2020/4378345 Webster A. C. Nagler E. V. Morton R. L. Masson P. (2017). Chronic kidney disease. Lancet London, Engl. 389, 1238–1252. 10.1016/S0140-6736(16)32064-5 Wiklander O. P. B. Bostancioglu R. B. Welsh J. A. Zickler A. M. Murke F. Corso G. (2018). Systematic methodological evaluation of a multiplex bead-based flow cytometry assay for detection of extracellular vesicle surface signatures. Front. Immunol. 9, 1326. 10.3389/fimmu.2018.01326 Witwer K. W. Buzás E. I. Bemis L. T. Bora A. Lässer C. Lötvall J. (2013). Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles 2. 10.3402/jev.v2i0.20360 Wu P. Tang Y. Jin C. Wang M. Li L. Liu Z. (2022). Neutrophil membrane engineered HucMSC sEVs alleviate cisplatin-induced AKI by enhancing cellular uptake and targeting. J. Nanobiotechnology 20, 353. 10.1186/s12951-022-01574-8 Xu R. Simpson R. J. Greening D. W. (2017). A protocol for isolation and proteomic characterization of distinct extracellular vesicle subtypes by sequential centrifugal ultrafiltration. Methods Mol. Biol. 1545, 91–116. 10.1007/978-1-4939-6728-5_7 Xu S. Cheuk Y. C. Jia Y. Chen T. Chen J. Luo Y. (2022). Bone marrow mesenchymal stem cell-derived exosomal miR-21a-5p alleviates renal fibrosis by attenuating glycolysis by targeting PFKM. Cell Death Dis. 13, 876. 10.1038/s41419-022-05305-7 Yang Y. Wang J. Zhang Y. Hu X. Li L. Chen P. (2022). Exosomes derived from mesenchymal stem cells ameliorate renal fibrosis via delivery of miR-186-5p. Hum. Cell 35, 83–97. 10.1007/s13577-021-00617-w Yu Y. Chen M. Guo Q. Shen L. Liu X. Pan J. (2023). Human umbilical cord mesenchymal stem cell exosome-derived miR-874-3p targeting RIPK1/PGAM5 attenuates kidney tubular epithelial cell damage. Cell Mol. Biol. Lett. 28, 12. 10.1186/s11658-023-00425-0 Zarantonello D. Rhee C. M. Kalantar-Zadeh K. Brunori G. (2021). Novel conservative management of chronic kidney disease via dialysis-free interventions. Curr. Opin. Nephrol. Hypertens. 30. 10.1097/MNH.0000000000000670 Zarjou A. Yang S. Abraham E. Agarwal A. Liu G. (2011). Identification of a microRNA signature in renal fibrosis: role of miR-21. Am. J. Physiol. Ren. Physiol. 301, F793–F801. 10.1152/ajprenal.00273.2011 Zarovni N. Corrado A. Guazzi P. Zocco D. Lari E. Radano G. (2015). Integrated isolation and quantitative analysis of exosome shuttled proteins and nucleic acids using immunocapture approaches. Methods 87, 46–58. 10.1016/j.ymeth.2015.05.028 Zha F. Qu X. Tang B. Li J. Wang Y. Zheng P. (2019). Long non-coding RNA MEG3 promotes fibrosis and inflammatory response in diabetic nephropathy via miR-181a/Egr-1/TLR4 axis. Aging (Albany NY) 11, 3716–3730. 10.18632/aging.102011 Zhang M. Johnson-Stephenson T. K. Wang W. Wang Y. Li J. Li L. (2022a). Mesenchymal stem cell-derived exosome-educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL-17(+) regulatory T cell. Stem Cell Res. Ther. 13, 484. 10.1186/s13287-022-03174-7 Zhang W. Zhou X. Zhang H. Yao Q. Liu Y. Dong Z. (2016). Extracellular vesicles in diagnosis and therapy of kidney diseases. Am. J. Physiology. Ren. Physiology 311, F844–F851. 10.1152/ajprenal.00429.2016 Zhang Y. Le X. Zheng S. Zhang K. He J. Liu M. (2022b). MicroRNA-146a-5p-modified human umbilical cord mesenchymal stem cells enhance protection against diabetic nephropathy in rats through facilitating M2 macrophage polarization. Stem Cell Res. Ther. 13, 171. 10.1186/s13287-022-02855-7 Zhang Z. Yu K. You Y. Jiang P. Wu Z. Deture M. A. (2023). Comprehensive characterization of human brain-derived extracellular vesicles using multiple isolation methods: implications for diagnostic and therapeutic applications. J. Extracell. Vesicles 12, e12358. 10.1002/jev2.12358 Zhao D. Tao W. Li S. Chen Y. Sun Y. He Z. (2021). Apoptotic body-mediated intercellular delivery for enhanced drug penetration and whole tumor destruction. Sci. Adv. 7, eabg0880. 10.1126/sciadv.abg0880 Zheng S. B. Zheng Y. Jin L. W. Zhou Z. H. Li Z. Y. (2018). Microvesicles containing microRNA-21 secreted by proximal tubular epithelial cells are involved in renal interstitial fibrosis by activating AKT pathway. Eur. Rev. Med. Pharmacol. Sci. 22, 707–714. 10.26355/eurrev_201802_14297 Zhong L. Liao G. Wang X. Li L. Zhang J. Chen Y. (2018). Mesenchymal stem cells-microvesicle-miR-451a ameliorate early diabetic kidney injury by negative regulation of P15 and P19. Exp. Biol. Med. (Maywood) 243, 1233–1242. 10.1177/1535370218819726 Zhuang Y. Zheng H. Yang Y. Ni H. (2022). GABA alleviates high glucose-induced podocyte injury through dynamically altering the expression of macrophage M1/M2-derived exosomal miR-21a-5p/miR-25-3p. Biochem. Biophys. Res. Commun. 618, 38–45. 10.1016/j.bbrc.2022.06.019 Zhu F. Chong L. E. E. Shin O. L. S. Pei G. Hu Z. Yang J. (2017). Adipose-derived mesenchymal stem cells employed exosomes to attenuate AKI-CKD transition through tubular epithelial cell dependent Sox9 activation. Oncotarget 8, 70707–70726. 10.18632/oncotarget.19979 Zou J. Shi M. Liu X. Jin C. Xing X. Qiu L. (2019). Aptamer-functionalized exosomes: elucidating the cellular uptake mechanism and the potential for cancer-targeted chemotherapy. Anal. Chem. 91, 2425–2430. 10.1021/acs.analchem.8b05204 Zubiri I. Posada-Ayala M. Benito-Martin A. Maroto A. S. Martin-Lorenzo M. Cannata-Ortiz P. (2015). Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes. Transl. Res. 166, 474–484. 10.1016/j.trsl.2015.05.007